131I-Labeled gold nanoframeworks for radiotherapy-combined second near-infrared photothermal therapy of cancer. Issue 45 (1st November 2021)

• Record Type: Journal Article
• Authors: Cheng, Danling; Gong, Jiali; Wang, Peng; Zhu, Jingyi; Yu, Ningyue; Zhao, Jinhua; Zhang, Qin; Li, Jingchao
• Is Part Of: Journal of materials chemistry. Volume 9:Issue 45(2021)
• Page Start: 9316
• Page End: 9323
• Publication Date: 2021-11-01
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d1tb02115j
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Radionuclide 131 I-labeled gold nanoframeworks ( 131 I-AuNFs) are developed for radiotherapy-combined second near-infrared photothermal therapy of breast cancer. Abstract : Photothermal therapy (PTT) has shown great promise for cancer treatment via light-triggered heat generation, while the anticancer efficacy of sole PTT is often limited. In this study, we report the use of radionuclide 131 I-labeled gold nanoframeworks ( 131 I-AuNFs) for radiotherapy-combined second near-infrared (NIR-II) PTT of breast cancer. AuNFs synthesized via a simple reduction approach are surface functionalized with polydopamine and poly(ethylene glycol), followed by labeling with 131 I. The formed 131 I-AuNFs with a high photothermal conversion efficacy and stable radioactivity can effectively accumulate into subcutaneous 4T1 mouse models as confirmed by in vivo single photon emission computed tomography (SPECT) imaging. Upon 1064 nm laser irradiation of tumors, local heat is generated for NIR-II PTT, which combines with radiotherapy to achieve a much higher therapeutic efficacy relative to sole treatment. As such, 131 I-AuNFs-mediated radiotherapy-combined NIR-II PTT results in the effective inhibition of the growth of subcutaneous tumors. This study thus provides a facile nanoplatform for effective combination cancer therapy.